Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Operating Leases (2020 - 2022)

Arcus Biosciences has reported Operating Leases over the past 3 years, most recently at $119.2 million for Q3 2022.

  • Quarterly results put Operating Leases at $119.2 million for Q3 2022, up 143.75% from a year ago — trailing twelve months through Sep 2022 was $119.2 million (up 143.75% YoY), and the annual figure for FY2021 was $116.9 million, up 666.82%.
  • Operating Leases for Q3 2022 was $119.2 million at Arcus Biosciences, down from $121.3 million in the prior quarter.
  • Over the last five years, Operating Leases for RCUS hit a ceiling of $121.3 million in Q2 2022 and a floor of $14.7 million in Q1 2021.
  • Median Operating Leases over the past 3 years was $82.3 million (2021), compared with a mean of $75.1 million.
  • Peak annual rise in Operating Leases hit 680.74% in 2022, while the deepest fall reached 143.75% in 2022.
  • Arcus Biosciences' Operating Leases stood at $15.2 million in 2020, then surged by 666.82% to $116.9 million in 2021, then rose by 1.97% to $119.2 million in 2022.
  • The last three reported values for Operating Leases were $119.2 million (Q3 2022), $121.3 million (Q2 2022), and $114.8 million (Q1 2022) per Business Quant data.